Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -$4.1 million.

  • Biodesix's Net Cash Flow rose 61.86% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.8 million, marking a year-over-year decrease of 227.97%. This contributed to the annual value of -$39,000 for FY2024, which is 99.77% up from last year.
  • Per Biodesix's latest filing, its Net Cash Flow stood at -$4.1 million for Q3 2025, which was down 231.93% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Net Cash Flow registered a high of $30.7 million during Q2 2024, and its lowest value of -$17.8 million during Q1 2023.
  • In the last 3 years, Biodesix's Net Cash Flow had a median value of -$5.2 million in 2024 and averaged -$2.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 562.17% in 2021, then spiked by 1,092.06% in 2022.
  • Over the past 5 years, Biodesix's Net Cash Flow (Quarterly) stood at -$15.2 million in 2021, then skyrocketed by 283.63% to $27.9 million in 2022, then tumbled by 76.91% to $6.4 million in 2023, then crashed by 180.09% to -$5.2 million in 2024, then spiked by 61.86% to -$4.1 million in 2025.
  • Its Net Cash Flow stands at -$4.1 million for Q3 2025, versus $3.1 million for Q2 2025 and -$8.6 million for Q1 2025.